A Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Study of Evaluating the Efficacy and Safety of CM326 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week double-blind randomized treatment period, and a 12-week safety follow-up period.
• Understand the study and voluntarily sign the informed consent form.
• Age ≥18 and ≤80 years old, male or female, weight ≥40 kg.
• The subject has been diagnosed with asthma for at least 1 year.
• Pre-bronchodilator FEV1 measured ≤80% of the normal predicted value.
• A positive bronchodilation test within 24 months before informed consent or at screening.
• The subject has received medium-to-high dose ICS combined with at least one control drug, such as LABA, LAMA, LTRA, Oral corticosteroids, theophylline, for at least 3 months before signing the informed consent, and maintained stable treatment regimen and dosage for at least 1 month before signing the informed consent.
• Asthma Control Questionnaire-5 (ACQ-6) score ≥1.5.
• Subjects must have experienced at least one severe asthma exacerbation event within 12 months before informed consent, and have not experienced a severe asthma exacerbation event within 30 days before informed consent.
• ≥ 80% compliance with usual asthma controller therapy in subjects during the screening phase
⁃ Voluntarily use highly effective contraception from the time of signing the informed consent form until 3 months after the last dose.